Meeting
2015 ASCO Annual Meeting
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of non-small cell lung cancer patients.
Authors
Antonio Marchetti
Center of Predictive Molecular Medicine, SS. Annunziata Hospital, University G. D'Annunzio, Chieti, Italy
Antonio Marchetti , John F. Palma , Lara Felicioni , Tommaso Martino De Pas , Rita Chiari , Maela Del Grammastro , Giampaolo Filice , Vienna Ludovini , Alba Ariela Brandes , Antonio Chella , Francesco Malorgio , Flavio Guglielmi , Michele De Tursi , Armando Santoro , Lucio Crino , Fiamma Buttitta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
EudraCT Number: 2010-023892-24
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8079)
DOI
10.1200/jco.2015.33.15_suppl.8079
Abstract #
8079
Poster Bd #
403
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
First Author: Karen L. Reckamp
Poster
2014 ASCO Annual Meeting
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.
First Author: Marzia Del Re
Poster
2013 ASCO Annual Meeting
Clinical implications of routine testing for epidermal growth factor receptor (EGFR) mutations in patients with nonsquamous non-small cell lung cancer (NSCLC).
First Author: Hui Zhu